• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019 Product Image

Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019

  • ID: 2758940
  • January 2014
  • Region: Global
  • 81 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Celgene Corporation
  • CombiMatrix Corporation
  • GE Healthcare
  • Johnson & Johnson
  • Mallinckrodt plc.
  • MORE

'Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019'

This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019.

The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report.

The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world.

The global trends such as drivers, restraints and opportunities of the global READ MORE >

FEATURED COMPANIES

  • Abbott Laboratories
  • Celgene Corporation
  • CombiMatrix Corporation
  • GE Healthcare
  • Johnson & Johnson
  • Mallinckrodt plc.
  • MORE

Chapter 1 Preface
1.1 Report description
1.2 Research Methodology
1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Nanomedicine Market Overview
3.1 Market Dynamics
3.1.1 Market Drivers
3.1.1.1 Improvement in technology for nanomedicine
3.1.1.2 Rising government support for research and development in nanomedicine
3.1.1.3 Presence of high unmet medical needs
3.1.1.4 Increase in investment amount and healthcare collaborations
3.1.1.5 High prevalence of chronic diseases
3.1.1.6 Impact Analysis of the Market Drivers
3.1.2 Market Restraints
3.1.2.1 Lack of organized regulatory framework
3.1.2.2 High costs involved
3.1.2.3 Impact Analysis of the Market Restraints
3.1.3 Market Opportunities
3.1.3.1 Presence of unmet medical needs in emerging economies
3.1.3.2 Identification of new medical applications
3.2 Porter's Five Forces Analysis: Global Nanomedicine Market
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of New entrants
3.2.4 Threat of Substitutes
3.2.5 Competitive Rivalry
3.3 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
3.4 Global Nanomedicine Market, 2011 – 2019 (USD Million)

Chapter 4 Global Nanomedicine Market, by Applications
4.1 Overview
4.2 Nanomedicine for Neurology
4.2.1 Global Nanomedicine for Neurology Market, 2011 – 2019 (USD Billion)
4.3 Nanomedicine for Cardiovascular (CVS)
4.3.1 Global Nanomedicine for Cardiovascular Market , 2011 – 2019 (USD Billion)
4.4 Nanomedicine for Oncology
4.4.1 Global Nanomedicine for Oncology Market , 2011 – 2019 (USD Billion)
4.5 Nanomedicine for Anti-inflammatory
4.5.1 Global Nanomedicine for Anti-Inflammatory Market, 2011 – 2019 (USD Billion)
4.6 Nanomedicine for Anti-infectives
4.6.1 Global Nanomedicine for Anti-Infectives Market, 2011 – 2019 (USD Billion)
4.7 Other Applications
4.7.1 Global Nanomedicine Market for Other Applications, 2011 – 2019 (USD Billion)
4.8 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (%)

Chapter 5 Global Nanomedicine Market, by Geography
5.1 Overview
5.1.1 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
5.2 North America
5.2.1 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
5.3 Europe
5.3.1 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
5.4 Asia-Pacific
5.4.1 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
5.5 Rest of the World
5.5.1 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)

Chapter 6 Recommendations
6.1 Collaborating with educational institutions to boost interdisciplinary education and training
6.2 Identifying and prioritizing key growth areas

Chapter 7 Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Overview
7.1.3 Product Portfolio
7.1.4 Business Strategies
7.1.5 Recent Developments
7.2 CombiMatrix Corporation
7.2.1 Company Overview
7.2.2 Financial Overview
7.2.3 Product Portfolio
7.2.4 Business Strategy
7.2.5 Recent Developments
7.3 Celgene Corporation
7.3.1 Company Overview
7.3.2 Financial Overview
7.3.3 Product Portfolio
7.3.4 Business Strategies
7.3.5 Recent Developments
7.4 Mallinckrodt plc.
7.4.1 Company Overview
7.4.2 Financial Overview
7.4.3 Product Portfolio
7.4.4 Business Strategies
7.4.5 Recent Developments
7.5 GE Healthcare
7.5.1 Company Overview
7.5.2 Financial Overview
7.5.3 Product Portfolio
7.5.4 Business Strategies
7.5.5 Recent Developments
7.6 Johnson & Johnson
7.6.1 Company Overview
7.6.2 Financial Overview
7.6.3 Product Portfolio
7.6.4 Business Strategies
7.6.5 Recent Developments
7.7 Merck & Company Inc.
7.7.1 Company Overview
7.7.2 Financial Overview
7.7.3 Product Portfolio
7.7.4 Business Strategies
7.7.5 Recent Developments
7.8 Nanosphere, Inc.
7.8.1 Company Overview
7.8.2 Financial Overview
7.8.3 Product Portfolio
7.8.4 Business Strategies
7.8.5 Recent Developments
7.9 Pfizer Inc.
7.9.1 Company Overview
7.9.2 Financial Overview
7.9.3 Product Portfolio
7.9.4 Business Strategies
7.10 Sigma-Tau Pharmaceuticals Inc.
7.10.1 Company Overview
7.10.2 Financial Overview
7.10.3 Product Portfolio
7.10.4 Business Strategies
7.10.5 Recent Developments
7.11 Teva Pharmaceutical Industries Ltd.
7.11.1 Company Overview
7.11.2 Financial Overview
7.11.3 Product Portfolio
7.11.4 Business Strategy
7.11.5 Recent Developments
7.12 UCB SA
7.12.1 Company Overview
7.12.2 Financial Overview
7.12.3 Product Portfolio
7.12.4 Business Strategies
7.12.5 Recent Developments

List of Figures

FIG. 1 Market Segmentation for the Nanomedicine Market
FIG. 2 Global Nanomedicine Market, by Application and Geography, 2012 (USD Billion)
FIG. 3 Porter's Five Forces Analysis: Global Nanomedicine Market
FIG. 4 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
FIG. 5 Global Nanomedicine Market, 2011 – 2019 (USD Billion)
FIG. 6 Global Nanomedicine for Neurology Market, 2011 - 2019 (USD Billion)
FIG. 7 Global Nanomedicine for Cardiovascular Market, 2011 - 2019 (USD Billion)
FIG. 8 Global Nanomedicine for Oncology Market, 2011 - 2019 (USD Billion)
FIG. 9 Global Nanomedicine for Anti-Inflammatory Market, 2011 - 2019 (USD Billion)
FIG. 10 Global Nanomedicine for Anti-Infective Market, 2011 - 2019 (USD Billion)
FIG. 11 Global Nanomedicine Market for Other Applications, 2011 - 2019 (USD Billion)
FIG. 12 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (Value %)
FIG. 13 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
FIG. 14 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
FIG. 15 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
FIG. 16 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
FIG. 17 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)
FIG. 18 Abbott Laboratories: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 19 CombiMatrix Corporation: Annual Sales, 2010 – 2012 (USD Million)
FIG. 20 Celgene Corporation: Annual Sales, 2010 – 2012 (USD Million)
FIG. 21 Covidien Plc.: – Annual Revenue, 2010 – 2012 (USD Million)
FIG. 22 GE Healthcare: Annual Revenue, 2010–2012 (USD Million)
FIG. 23 Johnson & Johnson: Medical Devices and Diagnostic Business Segment, Annual Revenue, 2010 – 2012 (USD Million)
FIG. 24 Merck & Co. Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 25 Nanosphere Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 26 Pfizer Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 27 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2010–2012 (USD Million)
FIG. 28 UCB S.A.: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Nanomedicine Market
TABLE 2 Impact Analysis of the Market Drivers for the Global Nanomedicine Market
TABLE 3 Impact Analysis of the Market Restraints for the Global Nanomedicine Market
TABLE 1 Global Nanomedicine Market, by Applications, 2011 -2019 (USD Billion)
TABLE 2 Global Nanomedicine Market, by Geography, 2011 - 2019 (USD Billion)

FEATURED COMPANIES

  • Abbott Laboratories
  • Celgene Corporation
  • CombiMatrix Corporation
  • GE Healthcare
  • Johnson & Johnson
  • Mallinckrodt plc.
  • MORE

The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario.Some of thedrivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others.

The global nanomedicine market is categorized into six segments on the basis of application, namely neurology, cardiovascular, anti-inflammatory, anti-infective, oncology and others.

Oncology held majority of the market share in 2012 on account of following factors:

- Presence of high number of commercialized nanomedicine products in the market
- Improved bioavailability and efficacy of the tumor specific nanomedicine enabling targeted drug delivery
- Rise in nanomedicine drug formulations replacing conventional drug formulations in cancer treatment

However, the global market for cardiovascular segment is expected to grow at the fastest pace owing to increasing prevalence of cardiovascular diseases demanding drugs with improved efficacy and therapeutic properties. Furthermore, realizing the importance and benefits of nanomedicine, researchers and manufacturers are striving to develop products with improved therapeutic properties in the cardiovascular segment.

The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia–Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region.In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region.China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.

- Abbott Laboratories
- Celgene Corporation
- CombiMatrix Corporation
- GE Healthcare
- Johnson & Johnson
- Mallinckrodt plc.
- Merck & Company Inc.
- Nanosphere, Inc.
- Pfizer Inc.
- Sigma-Tau Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos